Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53.

Lynparza (olaparib) - Merck (MSD), AstraZeneca

eprenetapopt (APR-246) - Aprea

http://www.ncbi.nlm.nih.gov/pubmed/40915175

Angelina Licor; Annahita Sallmyr; Eric J Devor; Geneva L Williams; Irina V Lagutina; Jamie L Padilla; Jun-yong Choe; Kimberly K Leslie; Lane E Smith; Mara P Steinkamp; Olufunmilola M Oyebamiji; Vernon S Pankratz; Yan Guo

Sep 8, 2025